Abstract Library

#2998 Inter- and Intrapatient Mean Absorbed Dose Variation and Simplification of Dosimetric Workflow after PRRT

Introduction: Post-PRRT dosimetry is not routinely performed, partly due to required multiple imaging time points. One time point imaging would reduce patient burden, and make dosimetry more applicable in the clinical settings.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Huizing D, Versleijen M, Martens E, Verheij M, Sinaasappel M,

Keywords: dosimetry, PRRT, simplification,

#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial

Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p<0.0001).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Li J

Authors: Li J, Xu J, Zhou Z, Bai C, Chi Y,

Keywords: extra-pancreatic, neuroendocrine tumors, safety,

#2284 The Association between Gastrin and Glucose Serum Concentration in Hypergastrinemic Patients with Gastric Neuroendocrine Tumors Type 1 and ECL-Cells Hyperplasia

Introduction: There is previous data demonstrating that elevated gastrin levels could exert some effect potentiating the glucose-induced insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mavroeidi V

Authors: Moschouris P, Mavroeidi V, Nikolopoulos G, Tsoli M, Karapanagioti A,

Keywords: Gastric Neuroendocrine Tumors Type 1, ECL-Cells Hyperplasia, gastrin, glucose,

#2283 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors

Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,

Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,

#2109 Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin +etoposide) is considered standard first-line palliative treatment. Etoposide is frequently administered intravenously, however oral etoposide is often used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- & intrapatient variability and patient compliance.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ali A

Authors: Ali A, Grönberg M, Hjortland G, Grønbæk H, Ladekarl M,

Keywords: chemotherapy, Neuroendocrine Neoplasms, Intravenous, Oral, survival,